CytomX Therapeutics, Inc..
CTMX.US | Research and experimental development on natural sciences and engineering
CytomX Therapeutics, Inc. is a biopharmaceutical company focused on developing conditionally activated therapeutics for the treatment of cancer. Their Probody therapeutics platform is designed to create antibody-based therapies that are activated specifically in the tumor microenvironment, aiming to...Show More
Better Health for All
-10
CytomX Therapeutics' entire business is devoted to developing cancer treatments. Its approved gene therapy, Adstiladrin®, achieved a 51% complete response rate in a clinical study for bladder cancer.
1
Another candidate, CX-2051, showed a 28% confirmed response rate in advanced colorectal cancer patients, with 43% at the upper expansion dose, which is significantly higher than the low to mid-single digit response rates of currently approved therapies.
2
The company's products are not associated with well-established negative health outcomes. However, clinical trials have reported adverse events; for CX-2029, 82.6% of patients experienced anemia (76.1% Grade 3), leading to a 3.3% discontinuation rate.
3
For CX-2051, 5 serious adverse events (1 Grade 2, 4 Grade 3) were reported among 25 patients.
4
The company's corporate governance guidelines (September 2025) mention identifying and addressing important risks.
5
The Code of Business Conduct and Ethics (April 2019) requires accurate and honest completion of records and full, fair, accurate, timely, and understandable disclosure in SEC reports.
6
As of December 31, 2023, 88 of 122 employees were primarily engaged in research and development activities.
7
The company's clinical trials are conducted under the supervision of qualified investigators in accordance with Good Clinical Practices (GCPs) and require independent Institutional Review Board (IRB) approval and monitoring.
8
Fair Money & Economic Opportunity
0
No evidence available to assess CytomX Therapeutics, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
20
The company's CEO total compensation to median employee compensation ratio was approximately 18 to 1 in 2020.
1
Employee engagement surveys from February 2026 show an average rating of 3.7 out of 5 stars (74/100) based on 35 reviews, with 67% of employees recommending the company to a friend.
2
The company offers a comprehensive array of benefits to its employees, including a variety of health insurance plans and a 401(k) plan with company matching contributions.
3
While the exact percentage of employees covered by health insurance is not specified, the description of a 'comprehensive array of benefits' suggests a high level of coverage. There is no public record of substantiated labor-law or human-rights violations, beyond a minor administrative delay in a Form 4 filing for a former officer.
4
Fair Trade & Ethical Sourcing
0
No evidence available to assess CytomX Therapeutics, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-20
CytomX Therapeutics has a whistleblower policy with an anonymous and confidential hotline, overseen by the Audit Committee.
1
Annual training sessions are conducted, and written acknowledgements are obtained from employees, officers, and directors, with a prohibition against retaliation.
2
However, the effectiveness of this program is not publicly measured. The company has not had any formal financial restatements, but did have minor disclosure tweaks with three late Form 4 filings for executive officers and directors in 2021 and 2023 due to administrative delays.
3
The Board of Directors has determined that all directors, except one, are independent, indicating approximately 85% of the board is conflict-free.
4
The company has an anti-corruption policy that complies with laws in all operating countries, prohibits bribery and kickbacks, and conducts annual training sessions with written acknowledgements.
5
However, it lacks customization for high-risk areas. The company engaged an external advisor to help create an ESG program and the compensation committee retained an independent consultant for executive compensation reviews, but the extent of independent verification of ethical claims is limited to approximately 45%.
6
Kind to Animals
-30
CytomX Therapeutics, Inc. is a biopharmaceutical company focused on research and development, and as such, does not have consumer products for cruelty-free certification, nor does it engage in animal agriculture or source related products like eggs, meat, or dairy. There is no information available regarding humane certifications for its animal-related operations, the auditing of animal-related suppliers for welfare compliance, or the use or substitution of animal-derived ingredients. The company's core business model also does not directly impact wildlife habitats or conservation. The company has "Significant involvement" in animal testing.
1
, using various animal models including mice (BALB/c nude, C57BL/6J, Beige/SCID, nu/nu) and Syrian golden hamsters in its research.
2
All animal experiments are performed in accordance with national laws (e.g., NIH Principles of Laboratory Animal Care, Dutch national law)
3
and are reviewed and approved by CytomX's Institutional Animal Care and Use Committee (IACUC Protocol AP303).
4
However, this policy focuses on compliance rather than articulating a commitment to reduce or prohibit animal testing. The company employs various in vitro methods, such as cell lines (MDA-MB-231, MC38, Daudi, HEK-blue IFN-a/b reporter cells), PBMC, dissociated tumors, and binding assays for early-stage experiments and activity reduction.
5
For example, conditionally activated IFN-a2b cytokines showed a 5,000X reduction in activity in vitro in its dual-masked form.
6
Despite this, animal models are consistently used for in vivo efficacy and safety studies, indicating that non-animal assays cover early-stage screens but are rarely used for complex endpoints.
No War, No Weapons
0
CytomX Therapeutics, Inc. is not involved in military contracting, indicating no revenue from arms or defense contracts.
1
The company is also not involved in the production or sale of controversial weapons.
2
As a biopharmaceutical company focused on research and development, it has no defense-related assets to divest.
Planet-Friendly Business
0
No publicly available data was found for any of the environmental performance metrics, including Scope 1, 2, and 3 greenhouse gas emissions, renewable energy consumption, water use, waste diversion, or the existence of science-based targets.
1
Information regarding environmental compliance violations, climate-related policies, or investments in climate-positive initiatives is also unavailable.
2
The company lacks documented targets or pledges for environmental action.
3
Respect for Cultures & Communities
0
CytomX Therapeutics, Inc. is a biopharmaceutical company focused on research and development.
1
There is no evidence of formal partnerships with indigenous or local community groups, which aligns with its business model.
2
Similarly, there are no reported cultural appropriation incidents,
3
nor is there mention of a cultural impact assessment protocol,
4
as the company's operational scope does not directly impact cultural contexts.
Safe & Smart Tech
0
No evidence available to assess CytomX Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific data or metrics related to waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education are provided for CytomX Therapeutics (CTMX.US) in the available articles.
1
The articles explicitly state significant data gaps regarding these zero waste and sustainable product metrics.
2